We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Vertex Pharmaceuticals Inc (VRTX) Com Stk

Sell:$432.51 Buy:$432.79 Change: $0.87 (0.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.87 (0.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.87 (0.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Contact details

50 Northern Avenue
United States
+1 (617) 3416393

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$111.10 billion
Shares in issue:
258.31 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Jeffrey Leiden
    Executive Chairman of the Board
  • Reshma Kewalramani
    President, Chief Executive Officer, Director
  • Charles Wagner
    Chief Financial Officer, Executive Vice President
  • Stuart Arbuckle
    Chief Operating Officer, Executive Vice President
  • David Altshuler
    Executive Vice President - Global Research, Chief Scientific Officer
  • Carmen Bozic
    Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
  • Amit Sachdev
    Executive Vice President, Chief Patient Officer
  • Bastiano Sanna
    Executive Vice President, Chief of Cell and Genetic Therapies
  • Ourania Tatsis
    Executive Vice President, Chief Regulatory and Quality Officer
  • Kristen Ambrose
    Senior Vice President, Chief Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.